Contact
searchSearch
HMP Global
Login

Home

Recent News

News
Delayed Interval Surgery After Extended Neoadjuvant Chemotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
05/26/2026
Stephanie Holland
Results from the 2 CHRONO trial demonstrated that delaying interval surgery until after 6 cycles of neoadjuvant chemotherapy did not significantly improve survival in advanced ovarian cancer.
Results from the 2 CHRONO trial demonstrated that delaying interval surgery until after 6 cycles of neoadjuvant chemotherapy did not significantly improve survival in advanced ovarian cancer.
Results from the 2 CHRONO trial...
05/26/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
05/26/2026
Stephanie Holland
Final subgroup analyses from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer.
Final subgroup analyses from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer.
Final subgroup analyses from the...
05/26/2026
Oncology
News
Carboplatin Plus Mirvetuximab Soravtansine Fails to Improve PFS in FRα-High Platinum-Eligible Recurrent Ovarian Cancer
05/26/2026
Stephanie Holland
Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival in patients with platinum-eligible relapsed ovarian cancer with high FRα expression.
Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival in patients with platinum-eligible relapsed ovarian cancer with high FRα expression.
Results from the phase 2...
05/26/2026
Oncology
News
Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer
05/26/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial showed durable PFS benefit with dostarlimab plus chemotherapy in dMMR/MSI-H advanced or recurrent endometrial cancer, with modeling analyses suggesting potential long-term cure in a substantial...
Updated results from the phase 3 RUBY trial showed durable PFS benefit with dostarlimab plus chemotherapy in dMMR/MSI-H advanced or recurrent endometrial cancer, with modeling analyses suggesting potential long-term cure in a substantial...
Updated results from the phase 3...
05/26/2026
Oncology
News
Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05/22/2026
Emily Estrada
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of...
05/22/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
FDA Approval
FDA Approves Datopotamab Deruxtecan for Patients With Triple-Negative Breast Cancer
05/22/2026
Emily Estrada
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the...
05/22/2026
Oncology
News
Ipatasertib Plus Fulvestrant and Palbociclib Shows Strong Preliminary Activity in HR-Positive, HER2-Negative Breast Cancer
05/21/2026
Stephanie Holland
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical...
05/21/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer
05/20/2026
Stephanie Holland
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial...
05/20/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use